Independent Study and Bioanalysis Suggests More Effective Nerve Repair and Faster Wound Healing
TORONTO, CANADA AND HAIFA, ISRAEL, August 13, 2025 /EINPresswire.com/ -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced that an independent study showed that exosomes produced by NurExone outperformed a recognized commercial industry standard in areas that strongly support key healing tasks including nerve repair, wound repair, calming the immune system and rebuilding tissue. This first independent analysis highlighted the broad potential of NurExone’s exosomes for both therapeutic and aesthetics markets.
“This data confirms that the naïve